HBV Treatment
EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B
- Details
- Category: HBV Treatment
- Published on Sunday, 08 May 2016 00:00
- Written by Liz Highleyman
Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.
EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 26 April 2016 00:00
- Written by Liz Highleyman
NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.
AASLD 2015: Hepatitis B Core Inhibitor NVR 3-778 Inhibits Viral Replication
- Details
- Category: Experimental HBV Drugs
- Published on Thursday, 21 January 2016 00:00
- Written by Liz Highleyman
Novira Therapeutics' NVR 3-778, a novel drug that interferes with the hepatitis B virus (HBV) core protein, blocked replication of various types of HBV in a laboratory study and reduced HBV viral load with no apparent safety issues in an early human trial, researchers reported at the AASLD Liver Meeting in November.
EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 April 2016 00:00
- Written by Liz Highleyman
The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
Chinese Herbs Taken with Lamivudine May Reduce Hepatitis B Mortality
- Details
- Category: Alternative & Complementary Therapy
- Published on Tuesday, 12 January 2016 00:00
- Written by Liz Highleyman
Hepatitis B patients who used traditional Chinese medicine, including the herbal preparation Jia-Wei-Xiao-Yao-San, while being treated with lamivudine (3TC or Epivir) were less likely to die of any cause than non-users, according to research published in the November 4, 2015, Journal of Enthopharmacology.
More Articles...
- Tenofovir Alafenamide Is Effective Against Hepatitis B with Less Kidney and Bone Toxicity
- Coverage of the 2015 AASLD Liver Meeting
- AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection
- Bone and Kidney Problems Uncommon Among Hepatitis B Patients on Long-term Antiviral Therapy
Web Design and Development by